Abstracts sources. Direct costs of diabetes complications and drug treatment were projected over patients' lifetimes from a UK National Health Service perspective. Both costs and QALYs were discounted at 3.5% p.a. Sensitivity analyses were performed. RESULTS: The model projected that treatment with IAsp would result in an additional 0.08 LYG and 0.09 QALYs per patient. Total lifetime costs/patient were estimated to increase by £419. The cost/LYG was calculated to be £5430 and cost/QALY £4825. CONCLUSION: The model predicted that treatment with insulin aspart would result in long-term improvements in health outcomes and quality of life compared to soluble human insulin in patients with type-1 diabetes. The cost-effectiveness result is well within the range considered to represent good value for money in the UK. In their evaluation of the cost effectiveness of insulin glargine, NICE included an assumption that switching to insulin would result in decreased health utility (8%). This altered notably any resulting cost-utility ratios. The purpose of this study was to test this hypothesis. METHODS: The design was a before-and-after study for type-2 patients who required switching to insulin. All followed an algorithm to achieve fasting and post-prandial blood glucose targets. Outcome measures included a measure of utilit (EQ5D index ) at baseline, three-months and sixmonths. This report was a preliminary analysis of the first 48 subjects, of which 32 had completed 12 weeks and 26 had completed the full 24-week study. RESULTS: Of the 26 subjects, 21 (81%) remained on glargine with or without OHAs, two required additional pre-meal boluses, and three required twicedaily pre-mixtures. The mean (SD) EQ5D index at baseline was 0.655 (0.275; n = 24), at three-months 0.637 (0.333; D vs. baseline NS) and at six-months 0.710 (0.319; D vs. baseline NS). At three-months, six patients had worse utility and six better utility, while 12 reported no change. At six-months, four patients had worse utility after switching, and 11 had better utility, the remaining nine subjects reported no change. Over the sixmonths, mean BMI increased from 29.4 to 30.0 kg/m 2 (n = 23, p < 0.001) and mean HbA1c decreased from 10.1% to 7.8% (n = 23, p < 0.001). Mean daily insulin dose at six-months was 61.6 units (range 24 to 178). CONCLUSIONS: This is a limited but important interim analysis. The hypothesis that switching to insulin-here insulin glargine-resulted in a notable decrease in utility (quality of life) was rejected, with a trend for a clinically meaningful improvement in utility. Economic evaluations should, therefore, exclude this assumption. This observation is not necessarily generalisable to all insulin regimens. Presence of cardiovascular co-morbidity in the year 2001 was identified using appropriate ICD-9 codes. Semi-logarithmic OLS models were used to estimate the impact of cardiovascular comorbidity on total and diabetes-related health care costs in year 2002, controlling for demographic characteristics (age, gender, race, and urban/rural location), presence of peripheral vascular conditions, cerebrovascular conditions, hypertension, hyperlipidemia, and other co-morbid conditions. Two-part models were used for estimating the impact of cardiovascular co-morbidity on specific costs such as ER/hospitalization, outpatient and prescription. Smearing estimates were used to interpret the results from the semi-logarithmic models. RESULTS: Presence of cardiovascular co-morbidity had a significant impact on all categories of total and diabetes-related health care costs, except diabetes-related prescription drug costs. Type-2 diabetes patients with cardiovascular co-morbidity had significantly higher total health care costs (38.9%, $12,550 vs. $9,031), ER/ hospitalization costs (239.8%, $4,845 vs. $1,426), outpatient costs (35.3%, $3,956 vs. $2,925) and prescription drug costs (15.1%, $4,686 vs. $4,071) compared to those without cardiovascular co-morbidity. Similarly, type-2 diabetes patients with cardiovascular co-morbidity had significantly higher diabetesrelated total health care costs (59.7%, $4349 vs. $2724), ER/hospitalization costs (346.8%, $1911 vs. $428) and outpatient costs (17.4%, $740 vs. $631) compared to patients without cardiovascular co-morbidity. CONCLUSIONS: Presence of cardiovascular co-morbidity in patients with type-2 diabetes significantly increases total and diabetes-related health care costs, with ER/hospitalization costs accounting for the highest percentage increase. 3 GlaxoSmithKline, Collegeville, PA, USA OBJECTIVE: To examine the impact of pre-existing depression on utilization patterns and adherence to oral hypoglycemic agents (OHAs) in patients newly diagnosed with type-2 diabetes. METHODS: Newly diagnosed type-2 diabetes patients during the three-year period (1998)(1999)(2000) were identified from a Medicaid claims database. Presence of pre-existing depression was determined on the basis of ICD-9 CM codes for depression. Utilization patterns (switching, augmentation) and adherence to OHAs were computed for a 12-month follow up period from the date of the index OHA prescription. A multivariate framework was used to estimate the impact of depression on utilization patterns and adherence, controlling for confounders such as demographics, co-morbidity, diabetes severity, regimen complexity, and interaction with health care providers. RESULTS: A total of 1326 newly diagnosed type-2 diabetes patients were identified (depressed = 471; non-depressed = 855). A significantly higher number of depressed patients (23.3%) switched or augmented therapy as compared to non-depressed patients (16.2%). Results of a multinomial logit model indicated that controlling for covariates, patients with depression were 1.7 times more likely to switch (p = 0.046) and two times more likely to augment
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